Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data

PharmacoEconomics Open
Jacqueline NicholasAndrew Lee

Abstract

Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of this study was to estimate healthcare resource utilization, costs, and relapse rates in the year after initiating treatment with dimethyl fumarate (DMF), interferon (IFN)-β, glatiramer acetate (GA), teriflunomide, or fingolimod in routine clinical practice for patients with MS who did not receive a DMT in the previous year. Patients initiating DMF, IFNβ, GA, teriflunomide, or fingolimod were identified based on claims data from 2012 to 2015 in the Truven MarketScan Commercial Claims Databases (n = 4194). Healthcare resource utilization assessment included the proportion of patients who were hospitalized, or had emergency room (ER) or urgent care (UC) visits. Healthcare costs were estimated for 1 year before and 1 year after DMT initiation. Relapse episodes were identified based on a published claims-based algorithm and clinical input from the research investigators. After DMT initiation, significant reductions in the proportions of patients who were hospitalized or requiring ER/UC visits we...Continue Reading

References

Aug 5, 2008·Journal of Neurology·Laura J JulianDavid C Mohr
Oct 31, 2008·Lancet·Alastair Compston, Alasdair Coles
Oct 5, 2010·Journal of Medical Economics·Benjamin J ChastekMaria V Lopez-Bresnahan
Feb 22, 2013·Journal of Medical Economics·Gabriel AdelmanKathleen F Villa
Nov 1, 2013·Clinical Pharmacology and Therapeutics·O H KantarciM Rodriguez
Jan 1, 2014·ClinicoEconomics and Outcomes Research : CEOR·Machaon M BonafedeCrystal Watson
Dec 7, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Tomas KalincikUNKNOWN MSBase Study Group
Mar 20, 2015·Multiple Sclerosis and Related Disorders·B A CohenH Zwibel
Apr 17, 2015·Multiple Sclerosis and Related Disorders·Jonathan D CampbellKavita Nair
Apr 30, 2015·Current Opinion in Neurology·Jiwon Oh, Paul W O'Connor
Feb 27, 2016·BMJ : British Medical Journal·Neil Pearce
Dec 7, 2016·Multiple Sclerosis and Related Disorders·Carrie M HershDaniel Ontaneda

❮ Previous
Next ❯

Citations

Nov 13, 2020·Patient Preference and Adherence·Jagadeswara R EarlaRajender R Aparasu
Dec 25, 2021·Multiple Sclerosis : Clinical and Laboratory Research·Huah Shin NgHelen Tremlett

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.